Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Head & Neck 1Gastrointestinal 1Dermatologic 1CNS 1Breast 1

Conditions

Head and Neck Neoplasms 3Squamous Cell Carcinoma of Head and Neck 2Breast Neoplasms 2Small Cell Lung Carcinoma 1Melanoma 1Laryngeal Diseases 1Gastrointestinal Neoplasms 1Central Nervous System Neoplasms 1Carcinoma, Non-Small-Cell Lung 1

Interventions

Peripheral Blood Stem Cell Transplantation 3Filgrastim 3Cisplatin 3selpercatinib 2pembrolizumab 2Etoposide 2Carboplatin 2regorafenib 1pentetreotide 1pazopanib 1etoposide phosphate 1epothilone B 1entrectinib 1durvalumab 1carbon-11 methionine 1cabozantinib 1aflibercept 1Thiotepa 1Temozolomide 1Tamoxifen 1Surveys and Questionnaires 1Radiotherapy 1Quality of Life 1Patient Reported Outcome Measures 1Paclitaxel 1Nivolumab 1NEO212 1Molecular Diagnostic Techniques 1Methionine 1MLN 8237 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Central Nervous System Neoplasms × MLN 8237 × Head & Neck × Clear all
NCT01639911 2019-07-22

Phase I Study of MLN8237 and Pazopanib in Patients With Solid Tumors

University of Illinois at Chicago

Phase 1 Completed
28 enrolled
BreastCNSDermatologicGastrointestinalHead & Neck

Breast Neoplasms, Gastrointestinal Neoplasms, Head and Neck Neoplasms, Melanoma, Central Nervous System Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡